May 17 2007, 7:00 AM EST
News source: Business Wire
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that results of 18 investigator-initiated trials related to the Company's products will be presented at Digestive Disease Week(R) 2007, which will be held May 19-24, 2007. Digestive Disease Week is considered the largest and most prestigious meeting in the world for the GI professional. Every year it attracts more than 16,000 physicians, researchers and academics from around the world who desire to stay up-to-date in their respective fields. The meeting is the year's best opportunity to learn about the latest advances in gastroenterology, hepatology, endoscopy and gastrointestinal surgery; prevention, diagnosis and treatment of digestive disorders; and cutting-edge technological advances.
POSTER PRESENTATIONS:
TOPIC LEAD AUTHOR DATE ---------------------------------------- -------------------- -------- XIFAXAN An open label series of rifaximin for A. Kornbluth, M.D. May 20 long term maintenance therapy for patients with refractory pouchitis History of hypothyroidism is associated E. Lauritano, M.D. May 20 to small intestinal bacterial overgrowth High dosage rifaximin for the treatment E. Scarpellini, M.D. May 20 of small intestinal overgrowth High recurrence of small intestinal E. Lauritano, M.D. May 20 bacterial overgrowth after antibiotic Rifaximin versus systemic antibiotics M. Gabrelli, M.D. May 20 for the treatment of small bowel bacterial overgrowth Small intestinal bacterial overgrowth in A. Parodi, M.D. May 20 acromegalic patients May breath test be useful in diagnosis A. Parodi, M.D. May 20 of IBS patients? an Italian Study The oral nonsystemic antibiotic H. DuPont, M.D. May 20 rifaximin prevents symptom recurrence in patients with recurrent C. difficile-associated diarrhea Characterization of C. difficile strain Z. Jiang, M.D. May 20 isolated from patients with hospital- associated diarrhea The effect of selective intestinal A. Saveriadis, M.D. May 20 decontamination on liver hemodynamics in patients with alcohol related decompensated cirrhosis Restless leg syndrome in patients with L. Weinstock, M.D. May 21 irritable bowel disease: response to bacterial overgrowth therapy Small intestinal bacterial overgrowth in L. Weinstock, M.D. May 21 patients with interstitial cystitis and gastrointestinal symptoms Double blind, randomized study to M. Lukas, M.D. May 22 evaluate efficacy and urinary excretional rate of two doses of rifaximin-EIR in mild to moderate active Crohn's disease (GRACE 02 study) Rifaximin as a steroid-sparing T. Shah, M.D. May 23 medication in the management of patients with mild to moderate inflammatory bowel disease Decreasing rates of colectomy despite M. Issa, M.D. May 23 high rates of hospitalization in C. difficile infected IBD patients: a tertiary referral center experience MOVIPREP Better efficacy of a new 2-liter bowel L. Clark May 22 cleansing preparation in the ascending colon Randomised and controlled clinical trial H. Gruss May 23 of polyethylene glycol with electrolytes and ascorbic acid in comparison to sodium phosphate for bowel preparation before colon cancer screening colonoscopy COLAZAL Efficacy and safety of balsalazide for J. Quiros May 22 treatment of pediatric patients with mild to moderate ulcerative colitis: A randomized double-blind study
CONTINUING MEDICAL EDUCATION ACTIVITES
In addition, Salix is supporting, through an unrestricted educational grant, two continuing medical education activities in conjunction with DDW this year:
Subscribe to RSS
Email
Print
Share
More News"Navigating the Clinical Maze of GI Disorders"
Faculty Chair
Gary Li
ADVERTISEMENT
INTERVIEW:
NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates
...MORE
NewsArticles BlogsADVERTISEMENT
Listen
Save
Comment
View All